Background It is still not certain whether it is worth using theophylline in
Perhaps more important but even more difficult to measure is the effect of treatment on the quality of life. Only one group of workers has used a method to quantify patients' feelings about their illness as well as the extent of their physical disability.'0 A further problem is that the relation between the plasma concentration and the effect of theophylline is not direct." The peak effect of a single dose may lag about four hours behind the peak of the plasma concentration. Some effect is present after the plasma concentration has fallen below the limit of detection.'2 Single dose studies or studies where a steady plasma concentration has not been achieved and maintained consistently throughout are therefore very likely to contain confounding errors. In addition, it seems possible that effects on the inflammatory response" 14 and their consequences are not detected by single dose or short term studies.
We report here a longer term study of the effects of theophylline, at two dosages of a slow release preparation, in patients with severe disease, based on simple spirometry, plethysmography, exercise testing, and quality of life measures. The study was double blind, placebo controlled, and crossed over, with steady state plasma concentrations maintained for at least six weeks for each phase.
Methods

SELECTION OF PATIENTS
We recruited in sequence all the new patients referred to our routine hospital chest clinic with stable chronic obstructive lung disease as defined by the American Thoracic Society. '5 We excluded all who could recall any previous theophylline treatment and those with any personal or family history suggesting asthma or atopy or evidence of any concurrent disease. Every effort was made to ensure that all suitable patients were admitted to the trial. The study was approved by the hospi-tal's research and ethical committee and all patients gave their informed written consent.
STUDY DESIGN
Patients attended for baseline measurements and were then randomly allocated to the order of treatment with placebo and low with high dose theophylline by a multiple (3 x 3) Latin square design. The three study periods were otherwise identical. Drug dosage was established in the first two weeks of each period as described below and maintained for five further weeks. At the end of the seventh week measurements of lung function, exercise capacity, and quality of life indices were done. All measurements were made at the same time of day for each patient. Resting pulse and blood pressure were also measured. Oxygen saturation, subjective breathlessness, and heart rate during exercise were also monitored as precautionary measures.
DETAILS OF DRUG DOSAGE
Each patient was prescribed identical tablets containing either 200 mg of theophylline or placebo, depending on the phase of the study. The starting dose in the first week of each study was 200 mg twice daily. The plasma concentration was measured at the end of this week and the dose necessary to achieve a steady state concentration of 10 mg/l (low dose) or 17 mg/l (high dose) was then determined for each individual by Bayesian parameter estimation (the OPT programme). '6 The plasma concentration was determined again at the end of the second week to confirm that the desired concentration was being achieved. The individual dosage based on these estimations was maintained for the remaining five weeks of that period of the study. A further plasma concentration was then obtained. Each of these samples was used to calculate theophylline clearances and the steady state concentration achieved. The placebo tablets were adjusted randomly at the same stage of the placebo period to maintain the blind.
Compliance was assessed by counting tablets. Six to fifteen extra tablets were supplied in each bottle and the number returned was counted at the next visit. Poor compliance was suspected if tablet counts diverged by more than five from the expected number. Only the pharmacist knew the treatment order and dosage regimen for each patient. Throughout the study all patients continued to take steady doses of their inhaled P agonists and ipratropium as prescribed. Those already having inhaled or oral steroids continued to take a constant dose. The same procedure was followed during each of the three stages of the study.
LUNG FUNCTION AND EXERCISE TESTS
PEF, FEV, and forced vital capacity (FVC) were determined as previously described. '7 The two stage vital capacity (VC) was determined as the sum of satisfactory tracings of the inspiratory capacity and of the expiratory reserve volume. Trapped gas volume (defined by Comroe's group'8) was the numerical difference between measurements of functional residual capacity made by the separate techniques of whole body plethysmography and closed circuit helium dilution. As the difference should be the same at all levels within a vital capacity we followed Chrystyn and colleagues'9 and measured at total lung capacity (TLC), using an automated method20 for constant volume plethysmography and a standard closed circuit apparatus (P K Morgan, model PTB).
Exercise performance was assessed by a symptom limited treadmill test based on that developed by Stark and Guz.2' Each patient chose the speed and slope of the treadmill that induced moderate dyspnoea after about five minutes' walking. The treadmill was run continuously at these same settings on each subsequent study day and was stopped when the patient decided to walk no further. This end point was not otherwise specified.
CHRONIC RESPIRATORY DISEASE QUESTIONNAIRE
We adopted the questionnaire developed by Guyatt et al'0 specifically to assess patients with severe respiratory disability. In it the patient chooses the five most important activities of regular daily life that invariably induce breathlessness. Each activity is scored separately on a seven point scale, where "no breathlessness" scores 7. Further questions are related to other aspects of life affected by respiratory disease namely, fatigue, emotional condition, and the feeling of control over the disease (mastery). These are scored in the same way. The results provide data in terms of rational numbers suitable for statistical analysis. For simplicity we have reported the scores on 0-100 scales.
STATISTICAL ANALYSIS
Clearance estimates following low and high doses were compared by means of paired Student's t tests. All response variables were analysed by two way analysis of variance to test for treatment effects at a level of 0 05. Follow up Bonferroni multiple comparisons provided overall 95% confidence intervals (CI) to identify specific within patient treatment differences. The resulting confidence intervals for the differences between the means for the active and the placebo treatment are presented in the results. The study was designed to. detect real differences of the order of 20% on the basis of the variances in comparable subjects reported in published studies with the conventional criterion for significance of <5% and 70% power. The loss of some patients (see below) and the variability in some measurements during the study reduced this expectation. The appropriate resulting minimum detectable differences are given in the results.
Results
Twenty patients were recruited, of whom 15 provided complete data for the placebo and high dose phases. One claimed never to have smoked, one was an ex-smoker of over 10 years' standing, and the rest were current smokers or had recently quitted smoking. All the smokers had had 20 cigarettes or more daily for at least 20 years. Table 1 gives the demographic details and baseline lung function, including percentage reversibility in response to 200 ug of salbutamol administered with a spacer device. One subject deteriorated rapidly during the last weeks of the study in his low dose phase and died in another hospital from respiratory failure. Thus 14 patients were included in the low dose phase. Patient 8 died of bronchopneumonia during the first phase of the study while on the high dose regimen. Patient 6 defaulted in the first (placebo) phase without explanation. Three (Nos 4, 7, 13) refused to continue on the grounds of nausea that they significantly (p < 0-001) higher than placebo at both low (CI 0-1 to 0 45 1) and high (CI 0O14 to 0-52 1) dosage. There was no significant difference in FEV, or FVC. The minimum detectable mean differences defined above for FEV, was 320 ml (38%) and for FVC 540 ml (31%). Figure 1 shows the individual changes in trapped gas volume with placebo and at the higher of the two steady state concentrations as it is significantly less (p < 0 05) at this level only (CI -1-17 to -0-02 1).
EXERCISE DATA
The distance walked at a constant work rate is shown in fig 2. The differences between the high dose and its placebo are significant (p < 0 05) with the 95% confidence intervals of the differences being 7 to 126 m. The low dose comparisons are not significantly differ- Figure 3 Self rated breathlessness scores in everyday activities (100 = "no symptoms") with placebo and at the higher average steady state plasma concentration (Cp,) of theophylline. with placebo and at the higher average steady state plasma concentration (Cps) of theophylline.
ent from either of them. Our minimum detectable mean difference proves to be 98 m or 53% of the overall mean.
QUALITY OF LIFE QUESTIONNAIRE Figure 3 shows that theophylline treatment improved subjective dyspnoea in everyday living (p < 0-005), averaging 15 If theophylline effects do include more than bronchodilation probably time will be needed for them to emerge. Some of the improvements recorded by our subjects after six weeks' treatment may be attributable to non-bronchodilator effects even though these were not measurable in themselves.
In conclusion, long term theophylline treatment with steady state plasma concentrations maintained at about' 17mg/l results' in useful improvements in the lives of many patients with clinically important obstructive disease without harmful effects.
